PRESS RELEASE: Initiator Pharma reports positive Phase IIa clinical data for IPED2015 in patients w


Initiator Pharma A/S, a clinical-stage biotech company that is developing a novel treatment of erectile dysfunction (ED), today announced statistically significant results on key efficacy endpoints in severe ED patients after a single administration of IPED2015. Moreover, no observations of critical adverse events were recorded.

The Phase IIa study which included patients suffering from servere Erectile Dysfunction (ED) has been completed satisfactorily. The study has demonstrated promising statistical significant efficacy data on ED. Besides, there has been no reporting of critical safety observations which is in line with the previously reported results from the Phase I trial in healthy volunteers.


The Phase IIa study which included patients suffering from servere Erectile Dysfunction (ED) has been completed satisfactorily. The study has demonstrated promising statistical significant efficacy data on ED. Besides, there has been no reporting of critical safety observations which is in line with the previously reported results from the Phase I trial in healthy volunteers.


To view the full press release please click this link: Initiator Pharma - Press Release

Source: Initiator Pharma

Further information: initiatorpharma.com

Featured Posts
Categories